As two Sullivan County men went through a life-saving kidney transplant on Wednesday, a worldwide audience checked in online to follow the progress of the surgery and ask questions of the medical team via Indiana’s first “Twittercast” of a live s…
Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL
Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or r…
'So I’m living for today'
Seven years ago, Justine Laymond lay on a hospital bed on life-support. After a double lung transplant, the 39-year-old British woman is a crew member on Edinburgh Inspiring Capital, the Scottish entrant in the Clipper Round the World Yacht Race. (CHRI…
Voluntary blood donation need of the hour – The Hindu
Zee NewsVoluntary blood donation need of the hourThe HinduLack of idea on medical and health benefits of donating blood or non-dissemination of knowledge on absence of any side effects in a healthy eligible male, …City people still hesitate in blood …
Aspirin vs warfarin: which is better? – Selby Times
Aspirin vs warfarin: which is better?Selby TimesHeart failure occurs when the heart can't pump enough blood around the body to … During the study, 2305 people with heart failure but no clear need to take …and more »
Millennium Highlights Updated Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Patients with …
Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited , today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or …
Cell Therapeutics Appoints New Chief Medical Officer – Business Review India (press release)
Cell Therapeutics Appoints New Chief Medical OfficerBusiness Review India (press release)The EMA's Committee for Medicinal Products for Human Use ("CHMP") has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial…
New method enhances adhesion of injected CECs for successful … – News-Medical.net
New method enhances adhesion of injected CECs for successful …News-Medical.net… that enhances the adhesion of injected corneal endothelial cells (CECs), allowing for successful corneal transplantation to repair pathological dysfunctions.and more&nb…
Cell Therapeutics Appoints New Chief Medical Officer – MarketWatch (press release)
Cell Therapeutics Appoints New Chief Medical OfficerMarketWatch (press release)… CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one …and …
Cell Therapeutics Appoints New Chief Medical Officer – PR Newswire (press release)
Cell Therapeutics Appoints New Chief Medical OfficerPR Newswire (press release)… CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one …and …